Clinical Trial Update: A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating guselkumab in adults with active psoriatic arthritis and inadequate response to anti-TNF therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Arthritis, Psoriatic | Phase 3 | Status: COMPLETED